{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:35:30Z","timestamp":1764401730274,"version":"3.41.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,8,6]],"date-time":"2017-08-06T00:00:00Z","timestamp":1501977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P40OD010960"],"award-info":[{"award-number":["5P40OD010960"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several<jats:italic>in\u00a0vitro<\/jats:italic>investigations have demonstrated that anticoagulant effects of fibrinogenolytic snake venom metalloproteinases have been abrogated in human plasma by modifying fibrinogen with iron (Fe) and carbon monoxide (<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>) to prevent catalysis or by directly inhibiting these enzymes with<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>. To translate these findings, we chose to assess the rabbit as a model of envenomation with<jats:italic>Crotalus atrox<\/jats:italic>venom. It was determined with thrombelastography that 15 times the concentration of venom noted to compromise coagulation in plasma<jats:italic>in\u00a0vitro<\/jats:italic>was required to cause coagulopathy<jats:italic>in\u00a0vivo<\/jats:italic>, likely secondary to venom binding to blood cells and being cleared from the circulation rapidly. Unlike human plasma, rabbit plasma pre\u2010treated with Fe\/<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>was not protected from fibrinogenolysis by venom. Consequently, the administration of purified human fibrinogen (with or without Fe\/<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>) would be required before venom administration to rabbits. Of greater interest, venom exposed to<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>had complete loss of fibrinogenolytic effect in rabbit plasma and partial loss of activity in whole blood, indicative of unbinding of<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>from venom and binding to haemoglobin. Thus, venom exposed to<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>could remain partially or completely inhibited in whole blood long enough for clearance from the circulation, allowing rabbits to be a useful model to test the efficacy of regional<jats:styled-content style=\"fixed-case\">CO<\/jats:styled-content>administration to the bite site. Future investigations are planned to test these novel approaches to attenuate venom\u2010mediated coagulopathy in the rabbit.<\/jats:p>","DOI":"10.1111\/bcpt.12848","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T14:26:38Z","timestamp":1499783198000},"page":"157-164","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characterization of the Rabbit as an<i>In Vitro<\/i>and<i>In Vivo<\/i>Model to Assess the Effects of Fibrinogenolytic Activity of Snake Venom on Coagulation"],"prefix":"10.1111","volume":"122","author":[{"given":"Vance G.","family":"Nielsen","sequence":"first","affiliation":[{"name":"The Department of Anesthesiology University of Arizona College of Medicine Tucson AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elda E.","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"National Natural Toxins Research Center and the Department of Chemistry Texas A&amp;M University\u2010Kingsville Kingsville TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Redford","sequence":"additional","affiliation":[{"name":"The Department of Anesthesiology University of Arizona College of Medicine Tucson AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12504"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MBC.0000000000000440","article-title":"Iron and carbon monoxide attenuate degradation of plasmatic coagulation by Crotalus atrox venom","volume":"27","author":"Nielsen VG","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MBC.0000000000000529","article-title":"Effect of iron and carbon monoxide on fibrinogenase\u2010like degradation of plasmatic coagulation by venoms of four Crotalus species","volume":"28","author":"Nielsen VG","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-016-9963-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6MD00336B"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1442-4"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12654"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.12.004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32834c7412"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(62)90086-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2131\/jts.11.135","article-title":"Plasma levels and urinary excretion of batroxobin and its defibrinogenating effects in various animal species","volume":"11","author":"Sugai K","year":"1986","journal-title":"J Toxicol Sci"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0022-3565(25)38643-X","article-title":"Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits","volume":"268","author":"Audebert F","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.10.007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.12.011"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cbpc.2016.10.009","article-title":"The binding effectiveness of anti\u2010r\u2010disintegrin polyclonal antibodies against disintegrins and PII and PIII metalloproteases: an immunological survey of type A, B and A+B venoms from Mohave rattlesnakes","volume":"191","author":"Cant\u00fa E","year":"2017","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(81)90085-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000128"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-0358.138961"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00298a010"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1861"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.V91.5.1582","article-title":"Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox","volume":"91","author":"Chang MC","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1999.1517"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80615-A"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.4.1162"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01166.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.07.019"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T22:23:39Z","timestamp":1750544619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bcpt.12848"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12848","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"type":"print","value":"1742-7835"},{"type":"electronic","value":"1742-7843"}],"subject":[],"published":{"date-parts":[[2017,8,6]]},"assertion":[{"value":"2017-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}